|
|
Article: Levitra(TM) (vardenafil HCl) Approved for the Treatment of Erectile Dysfunction by European Commission; A New Treatment Option Could Mean Improved Sexual Performance for Some 30 Million Men(1) Affected by Erectile Dysfunction in Europe.
- Article from:
- PR Newswire
- Article date:
- March 7, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Bayer HealthCare of Bayer AG [DAX and NYSE: BAY] and GlaxoSmithKline plc [LSE and NYSE: GSK] announced today that they have received marketing authorisation from the European Commission for Levitra(TM) (vardenafil HCl), a new oral PDE-5 inhibitor for the treatment of male erectile dysfunction (ED). The decision follows a positive opinion by the European Committee for Proprietary Medicinal Products (CPMP) on 21 November 2002. Bayer and GSK anticipate launching Levitra as soon as possible in European markets. The drug has also been approved by regulatory authorities in several Latin American countries and has been submitted for approval to regulatory agencies in all major ...
Related newspaper, magazine, and journal articles:
|
|
Article: Nine in Ten Men Report Improvement in Erections with ...
PR Newswire;
June 30, 2003 ;
700+ words
... ... development agreement for LEVITRA in November 2001. The U ... issued an approvable letter for LEVITRA in July 2002. LEVITRA was approved on March 6 ... the worldwide operations of Bayer HealthCare, a subgroup of Bayer AG ...
|
|